Spots Global Cancer Trial Database for cellular therapy
Every month we try and update this database with for cellular therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT03691376 | Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Sensit... Platinum-Sensit... Platinum-Sensit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Refractory Fall... Refractory Ovar... Refractory Prim... | Aldesleukin Autologous NY-E... Cellular Therap... Melphalan | 18 Years - | Roswell Park Cancer Institute | |
| A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product | NCT05768269 | Hematological M... Solid Tumor Mal... | No Intervention | 18 Years - | Century Therapeutics, Inc. | |
| 3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma | NCT02057445 | Non-Hodgkins Ly... Hodgkins Lympho... Lymphoprolifera... | EBV CTL's Peripheral Bloo... | 1 Year - | New York Medical College | |
| A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis | NCT06384976 | Multiple Sclero... Multiple Sclero... Multiple Sclero... | KYV-101 Standard lympho... Anti-CD20 mAB | 18 Years - 60 Years | Kyverna Therapeutics | |
| Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma | NCT01636388 | Hodgkins Lympho... | allogeneic dono... | - 45 Years | New York Medical College | |
| Cellular Therapy With Cord Blood Cells | NCT00427557 | Multiple Myelom... Leukemia Lymphoma | Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo... | - 80 Years | M.D. Anderson Cancer Center | |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | NCT05686226 | Cervical Cancer Throat Cancer Oropharynx Canc... Anal Cancer Vulva Cancer Vaginal Cancer Penile Cancer Metastatic Canc... HPV-Related Mal... HPV-Related Car... HPV-Related Cer... HPV-Related Squ... HPV-Related Ade... HPV Positive Or... HPV-Associated ... HPV-Related Ade... HPV-Related End... HPV-Related Ana... HPV-Related Pen... HPV-Related Vul... HPV Positive Re... | E7 TCR-T cells | 18 Years - | Rutgers, The State University of New Jersey | |
| Cellular Therapy With Cord Blood Cells | NCT00427557 | Multiple Myelom... Leukemia Lymphoma | Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo... | - 80 Years | M.D. Anderson Cancer Center | |
| Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer | NCT00026897 | Neoplasm | Gamma-camera im... Low-risk biopsy | - | National Institutes of Health Clinical Center (CC) | |
| ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells | NCT06090864 | Hodgkin Lymphom... Relapse Refractory | Chemotherapy Cell infusion | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | NCT06347068 | Breast Cancer Relapse Resistant Cance... Triple Negative... | iC9-CAR.B7-H3 T... cyclophosphamid... fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Adoptive Cellular Therapy and Radiation Therapy After Surgery in Treating Patients With Esophageal Cancer | NCT01691664 | Esophageal Canc... | Only radiation ... Radiation thera... | 18 Years - | Capital Medical University | |
| ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | NCT04319757 | Locally Advance... Metastatic Canc... Solid Tumor HER2-positive G... HER2-positive M... | ACE1702 Cyclophosphamid... Fludarabine | 18 Years - | Acepodia Biotech, Inc. | |
| A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis | NCT06193889 | Myasthenia Grav... Generalized Mya... | KYV-101 Standard lympho... | 18 Years - 75 Years | Kyverna Therapeutics | |
| A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product | NCT05768269 | Hematological M... Solid Tumor Mal... | No Intervention | 18 Years - | Century Therapeutics, Inc. | |
| Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma | NCT04523688 | Glioblastoma Vaccination | Autologous Dend... Temozolomide | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type | NCT05218408 | Astrocytoma, Gr... Glioblastoma Giant Cell Glio... Glioblastoma Mu... | CYNK-001 system... | 18 Years - | Celularity Incorporated | |
| Patient Reported Outcomes and Patient Education in Cellular Therapy Patients | NCT04853277 | Stem Cell Trans... CAR T-Cell Tran... CAR T-Cell Ther... Cellular Therap... Hematopoietic S... HSCT Multiple Myelom... Leukemia Lymphoma | Education | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| FT819 in Subjects With B-cell Malignancies | NCT04629729 | Lymphoma, B-Cel... Chronic Lymphoc... Precursor B-Cel... | FT819 Cyclophosphamid... Fludarabine IL-2 Bendamustine | 18 Years - | Fate Therapeutics | |
| Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease | NCT04744116 | Hematopoietic a... Steroid Refract... | Cellular Therap... Ruxolitinib | 12 Years - 80 Years | M.D. Anderson Cancer Center | |
| Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients | NCT05164016 | Cancer Hematopoietic S... Transplant-Rela... Solid Tumor Mal... Hematologic Mal... Solid Organ Tra... Hematopoietic C... Cellular Therap... | - 24 Years | St. Jude Children's Research Hospital | ||
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | NCT03841110 | Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small Cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car... | FT500 Nivolumab Pembrolizumab Atezolizumab Cyclophosphamid... Fludarabine IL-2 | 18 Years - | Fate Therapeutics | |
| A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy | NCT04923893 | Multiple Myelom... | Bortezomib Dexamethasone Lenalidomide Cilta-cel Cyclophosphamid... Fludarabine | 18 Years - | Janssen Research & Development, LLC | |
| ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | NCT04319757 | Locally Advance... Metastatic Canc... Solid Tumor HER2-positive G... HER2-positive M... | ACE1702 Cyclophosphamid... Fludarabine | 18 Years - | Acepodia Biotech, Inc. | |
| Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | NCT06347068 | Breast Cancer Relapse Resistant Cance... Triple Negative... | iC9-CAR.B7-H3 T... cyclophosphamid... fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells | NCT06305299 | Ovary Neoplasm Ovarian Cancer Epithelial Ovar... Recurrent | iC9-CAR.B7-H3 T... Cyclophosphamid... Fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease | NCT04744116 | Hematopoietic a... Steroid Refract... | Cellular Therap... Ruxolitinib | 12 Years - 80 Years | M.D. Anderson Cancer Center | |
| Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients | NCT05164016 | Cancer Hematopoietic S... Transplant-Rela... Solid Tumor Mal... Hematologic Mal... Solid Organ Tra... Hematopoietic C... Cellular Therap... | - 24 Years | St. Jude Children's Research Hospital | ||
| A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma | NCT05257083 | Multiple Myelom... | Daratumumab Bortezomib Lenalidomide Dexamethasone Cilta-cel Cyclophosphamid... Fludarabine | 18 Years - | Stichting European Myeloma Network | |
| A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | NCT04383067 | Metastatic Urot... | Tumor Infiltrat... Proleukin | 18 Years - | Sheba Medical Center | |
| Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer | NCT04847466 | Gastroesophagea... Advanced HNSCC | N-803 Pembrolizumab PD-L1 t-haNK | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| CD30 CAR for CD30+ NSGCT | NCT05634785 | Germ Cell Tumor Nonseminomatous... | ATLCAR.CD30 Cel... Cyclophosphamid Fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma | NCT03506802 | HLA-A*0201 Posi... NY-ESO-1 Positi... Recurrent Plasm... Refractory Plas... | 18F-FHBG Aldesleukin Cellular Therap... Computed Tomogr... Filgrastim Laboratory Biom... Lenalidomide Leukapheresis Melphalan Plerixafor Positron Emissi... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation | NCT05181540 | Hodgkin Lymphom... Non Hodgkin Lym... | AB-205 Placebo | 40 Years - | Angiocrine Bioscience | |
| FT538 in Subjects With Advanced Hematologic Malignancies | NCT04614636 | Acute Myeloid L... AML, Adult Multiple Myelom... Myeloma | FT538 Cyclophosphamid... Fludarabine Daratumumab Elotuzumab | 18 Years - | Fate Therapeutics | |
| A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis | NCT06193889 | Myasthenia Grav... Generalized Mya... | KYV-101 Standard lympho... | 18 Years - 75 Years | Kyverna Therapeutics | |
| A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | NCT04383067 | Metastatic Urot... | Tumor Infiltrat... Proleukin | 18 Years - | Sheba Medical Center | |
| Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer | NCT00026897 | Neoplasm | Gamma-camera im... Low-risk biopsy | - | National Institutes of Health Clinical Center (CC) | |
| A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma | NCT04133636 | Multiple Myelom... | JNJ-68284528 Lenalidomide Daratumumab Bortezomib Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation | NCT05181540 | Hodgkin Lymphom... Non Hodgkin Lym... | AB-205 Placebo | 40 Years - | Angiocrine Bioscience | |
| RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | NCT06359041 | Generalized Mya... | CABA-201 | 18 Years - 70 Years | Cabaletta Bio | |
| A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma | NCT04133636 | Multiple Myelom... | JNJ-68284528 Lenalidomide Daratumumab Bortezomib Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies | NCT05237206 | Oncology | SUPLEXA | 18 Years - | Alloplex Biotherapeutics Inc | |
| Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer | NCT03240861 | HLA-A*0201 Posi... Locally Advance... NY-ESO-1 Positi... Unresectable Ma... Sarcoma | 18F-FHBG Aldesleukin Busulfan Cellular Therap... Computed Tomogr... Filgrastim Fludarabine Leukapheresis Plerixafor Positron Emissi... | 16 Years - | Jonsson Comprehensive Cancer Center | |
| FT819 in Subjects With B-cell Malignancies | NCT04629729 | Lymphoma, B-Cel... Chronic Lymphoc... Precursor B-Cel... | FT819 Cyclophosphamid... Fludarabine IL-2 Bendamustine | 18 Years - | Fate Therapeutics | |
| A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy | NCT04923893 | Multiple Myelom... | Bortezomib Dexamethasone Lenalidomide Cilta-cel Cyclophosphamid... Fludarabine | 18 Years - | Janssen Research & Development, LLC | |
| FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | NCT04551885 | Solid Tumor, Ad... | FT516 Avelumab Cyclophosphamid... Fludarabine IL-2 | 18 Years - | Fate Therapeutics | |
| A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | NCT04383067 | Metastatic Urot... | Tumor Infiltrat... Proleukin | 18 Years - | Sheba Medical Center | |
| CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type | NCT05218408 | Astrocytoma, Gr... Glioblastoma Giant Cell Glio... Glioblastoma Mu... | CYNK-001 system... | 18 Years - | Celularity Incorporated | |
| FT538 in Subjects With Advanced Hematologic Malignancies | NCT04614636 | Acute Myeloid L... AML, Adult Multiple Myelom... Myeloma | FT538 Cyclophosphamid... Fludarabine Daratumumab Elotuzumab | 18 Years - | Fate Therapeutics | |
| Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma | NCT03570892 | Non-Hodgkin Lym... | Tisagenlecleuce... Platinum-based ... | 18 Years - | Novartis | |
| Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | NCT06347068 | Breast Cancer Relapse Resistant Cance... Triple Negative... | iC9-CAR.B7-H3 T... cyclophosphamid... fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation | NCT05181540 | Hodgkin Lymphom... Non Hodgkin Lym... | AB-205 Placebo | 40 Years - | Angiocrine Bioscience |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
